A carregar...

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

Pacritinib (SB1518) is a Janus kinase 2 (JAK2), JAK2(V617F), and Fms-like tyrosine kinase 3 inhibitor that does not inhibit JAK1. It demonstrated a favorable safety profile with promising efficacy in phase 1 studies in patients with primary and secondary myelofibrosis (MF). This multicenter phase 2...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Komrokji, Rami S., Seymour, John F., Roberts, Andrew W., Wadleigh, Martha, To, L. Bik, Scherber, Robyn, Turba, Elyce, Dorr, Andrew, Zhu, Joy, Wang, Lixia, Granston, Tanya, Campbell, Mary S., Mesa, Ruben A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2015
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4490373/
https://ncbi.nlm.nih.gov/pubmed/25762180
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-02-484832
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Internet

https://ncbi.nlm.nih.gov/pmc/articles/PMC4490373/
https://ncbi.nlm.nih.gov/pubmed/25762180
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-02-484832
Cannot write session to /tmp/vufind_sessions/sess_91c1u3feld8d8kg35ivteuvul4